rs4143815- PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy
- PMID: 31035590
- PMCID: PMC6539607
- DOI: 10.3390/ijms20092082
rs4143815- PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy
Abstract
Up to 30-50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients' treatment. The aim of this study is to define the immunogenetic biomarkers of 10 year BCR (primary aim), 10 year overall survival (OS) and 5 year BCR (secondary aims). In this mono-institutional retrospective study, 549 Caucasian patients (a discovery set n = 418; a replication set n = 131) were affected by locally advanced PCa and homogeneously treated with RT. In the training set, associations were made between 447 SNPs in 77 genes of the immune system; and 10 year BCR and 10 year OS were tested through a multivariate Cox proportional hazard model. Significant SNPs (p-value < 0.05, q-value < 0.15) were analyzed in the replication set. Replicated SNPs were tested for 5 year BCR in both sets of patients. A polymorphism in the PDL1 gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: p = 0.003, HR (95% CI) = 0.58 (0.41-0.83); replication set: p = 0.063, HR (95% CI) = 0.52 (0.26-1.04)) that was significantly associated with 5 year BCR (training set: p = 0.009, HR (95% CI) = 0.59 (0.40-0.88); replication set: p = 0.036, HR (95% CI) = 0.39 (0.16-0.94)). No biomarkers of OS were replicated. rs4143815-PDL1 arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.
Keywords: biochemical recurrence; biomarker; immunogenetics; prostate cancer; radiotherapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.Oncotarget. 2016 Aug 16;7(33):53309-53320. doi: 10.18632/oncotarget.10786. Oncotarget. 2016. PMID: 27462860 Free PMC article.
-
Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.Cancer Med. 2019 Jun;8(6):2777-2783. doi: 10.1002/cam4.2163. Epub 2019 Apr 16. Cancer Med. 2019. PMID: 30993852 Free PMC article.
-
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.Oncotarget. 2016 Nov 29;7(48):79943-79955. doi: 10.18632/oncotarget.13161. Oncotarget. 2016. PMID: 27835597 Free PMC article.
-
Immunogenetics of prostate cancer: a still unexplored field of study.Pharmacogenomics. 2018 Feb;19(3):263-283. doi: 10.2217/pgs-2017-0163. Epub 2018 Jan 12. Pharmacogenomics. 2018. PMID: 29325503 Review.
-
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.Front Oncol. 2016 Feb 16;6:24. doi: 10.3389/fonc.2016.00024. eCollection 2016. Front Oncol. 2016. PMID: 26909338 Free PMC article. Review.
Cited by
-
Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer.Curr Oncol. 2023 Jun 2;30(6):5409-5424. doi: 10.3390/curroncol30060410. Curr Oncol. 2023. PMID: 37366893 Free PMC article.
-
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.Mol Ther. 2021 Jun 2;29(6):1958-1969. doi: 10.1016/j.ymthe.2021.04.029. Epub 2021 Apr 29. Mol Ther. 2021. PMID: 33932597 Free PMC article. Review.
-
Bacteroides thetaiotaomicron and Lactobacillus johnsonii modulate intestinal inflammation and eliminate fungi via enzymatic hydrolysis of the fungal cell wall.Sci Rep. 2020 Jul 13;10(1):11510. doi: 10.1038/s41598-020-68214-9. Sci Rep. 2020. PMID: 32661259 Free PMC article.
References
-
- Xie W., Regan M.M., Buyse M., Halabi S., Kantoff P.W., Sartor O., Soule H., Clarke N.W., Collette L., Dignam J.J., et al. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J. Clin. Oncol. 2017;35:3097–3104. doi: 10.1200/JCO.2017.73.9987. - DOI - PMC - PubMed
-
- De Langhe S., De Ruyck K., Ost P., Fonteyne V., Werbrouck J., De Meerleer G., De Neve W., Thierens H. Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene. Int. J. Radiat. Oncol. Biol. Phys. 2013;85:393–399. doi: 10.1016/j.ijrobp.2012.02.061. - DOI - PubMed
-
- Langsenlehner T., Thurner E.M., Renner W., Gerger A., Kapp K.S., Langsenlehner U. Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy. Strahlenther. Onkol. 2014;190:364–369. doi: 10.1007/s00066-013-0503-2. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials